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SUMMARY
Asymptomatic and obligatory liver stage (LS) infection of Plasmodium parasites presents an attractive target for antimalarial vaccine and
drug development. Lack of robust cellular models to study LS infection has hindered the discovery and validation of host genes essential
for intrahepatic parasite development. Here, we present a chemically differentiated mouse embryonic stem cell (ESC)-based LS model,
which supports complete development of Plasmodium berghei exoerythrocytic forms (EEFs) and can be used to define new host-parasite
interactions. Using our model, we established that host Pnpla2, coding for adipose triglyceride lipase, is dispensable for P. berghei EEF
development. In addition, we also evaluated in-vitro-differentiated human hepatocyte-like cells (iHLCs) to study LS of P. berghei and found
it to be a sub-optimal infection model. Overall, our results present a new mouse ESC-based P. berghei LS infection model that can be utilized to study the impact of host genetic variation on parasite development.

INTRODUCTION
Malaria is a devastating mosquito-borne infectious disease
which caused an estimated 405,000 deaths worldwide in
2018, with 93% of the cases occurring in Africa (World
Health Organization, 2019). A cycle of human malaria
infection begins when an infected Anopheles mosquito inoculates Plasmodium sporozoites into the skin of a vertebrate host (Amino et al., 2006), from where the parasites
trickle into the circulation and migrate toward liver to
invade hepatocytes and form exoerythrocytic forms
(EEFs) enclosed within the parasitophorous vacuole. Targeting the liver stage (LS) of Plasmodium parasites with antimalarial drugs and vaccines is an attractive strategy to interrupt infection, as this is an obligatory and asymptomatic
phase of infection that leads to the onset of symptomatic
intra-erythrocytic schizogony. Furthermore, human malaria parasites, such as, P. vivax and P. ovale, produce
dormant liver forms, or hypnozoites, which serve as a reservoir of infection (Wells et al., 2010).
Discovery of novel host-parasite interactions crucial for
EEF development has been severely inhibited due to lack
of robust and reproducible genetically tractable malaria
LS cellular models. So far, mainly human and mouse liver
cancer cell lines (Huh7, HepG2, Hepa1-6), hepatic cell lines
(HC04), and primary hepatocytes have been utilized for
this purpose (Prudêncio et al., 2011). More recently, micro-patterned human hepatocyte-murine embryonic fibroblasts co-cultures (MPCCs) and in-vitro-differentiated human hepatocyte-like cells (iHLCs) were described as well

(March et al., 2013; Ng et al., 2015). Although cell lines
are convenient to maintain and have a well-characterized
genome and transcriptome, they are immortalized, and
show dysregulated gene expression and abnormal
signaling. For instance, hepatoma cells exhibit low abundance of drug metabolizing enzymes and transporters
(Guo et al., 2011), altered glycogen synthase kinase 3b
(Desbois-mouthon et al., 2002), and Toll-like receptor 3
signaling (Khvalevsky et al., 2007), thus, displaying phenotypes not observed in primary hepatocytes. Primary hepatocytes, instead, have limited availability, short lifespan,
and lose their hepatic features rapidly in vitro. In addition,
both, primary hepatocytes and hepatoma cell lines are acquired from a small group of donors thus representing
limited genetic diversity within the population.
Conversely, induced pluripotent stem cells (iPSCs), can be
derived from diverse human subjects thus allowing generation of customized infection models and studying
donor-specific infection phenotypes or responses.
Mouse embryonic stem cells (ESCs) and human iPSCs are
normal cells with virtually unlimited proliferative abilities
that are highly amenable to genetic manipulation (Sander
and Joung, 2014; Shen et al., 2014) and share the capacity
to differentiate into many different cell types (Sterneckert
et al., 2014). In addition to self-renewal and pluripotency,
large resources of stem cell lines are now available to explore
mouse gene functions or investigate the impact of human
genetic variation in the context of pathogen-host interactions (Elling et al., 2017; Kilpinen et al., 2017). These features of pluripotent stem cells (PSCs) has facilitated the
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development of genetically tractable PSC-based infection
models for several pathogens, such as, Plasmodium parasites,
Salmonella typhimirium, and hepatitis C virus (Ng et al., 2015;
Schwartz et al., 2012; Yeung et al., 2015; Yiangou et al.,
2016). With respect to iHLCs, liver infection models for hepatitis C virus and Plasmodium spp. have been reported (Ng
et al., 2015; Schwartz et al., 2012). For malaria specifically,
iHLCs have been shown to support the development of
various human and rodent Plasmodium spp. up to mature
schizonts (Ng et al., 2015). In addition, erythrocytes derived
from mouse ESCs have also been shown to be successfully
infected with P. berghei blood stages (Yiangou et al., 2016).
These developments indicate that usage of human and
mouse PSCs in infectious disease research is opening up a
new strategy to interrogate host-parasite interactions and
can exploit existing resources, such as the Knockout Mouse
Project repository. To investigate ways of leveraging this potential for research into the LS of malaria parasites, we
explored both human and mouse PSC-based infection
models to study P. berghei liver infection.
Primarily, in this study, we explored 3-methoxybenzamide (MBA)-differentiated mouse ESCs as a model to study
P. berghei LS infection. MBA treatment of mouse ESCs presents a short, 3-day chemical differentiation method that
produces large, terminally differentiated epithelial-like
cells, as opposed to 25- to 35-day-long protocols for generating iHLCs. Because P. berghei sporozoites are highly promiscuous and can infect a variety of differentiated cell
types, we hypothesized that MBA-differentiated mouse
ESCs may be permissive to infection too, and could provide
a new malaria LS infection model. Our results show that
MBA-differentiated mouse ESCs support full development
of P. berghei EEFs characterized by formation of large liver
schizonts and release of infectious merosomes. We utilized
this model to screen for host genes required for LS parasite
development. In particular, we assessed the role of mouse
Pnpla2, coding for adipose triglyceride lipase (ATGL), in
P. berghei LS development in MBA-differentiated mouse
ESCs, since preliminary small interfering RNA (siRNA)
screening in Huh7 human hepatoma cells showed a negative impact on EEF development upon ATGL knockdown
(see Results). In parallel, we re-examined the suitability of
human PSC-derived iHLCs to study P. berghei LS infection
in vitro. Our findings suggest that fully differentiated iHLCs
(day 26 of differentiation) can be infected by P. berghei sporozoites but do not support complete development of EEFs,
as depicted by the presence of small intrahepatic parasites
several hours post-invasion, abnormal merozoite surface
protein-1 (MSP-1) staining in liver schizonts, and lack of infectious merosomes. Overall, our results demonstrate a
robust genetically modifiable mouse ESC-based P. berghei
LS infection model which can be used to study novel
and/or validate existing host-parasite interactions.
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RESULTS
MBA-Differentiated Mouse ESCs Support Complete
Development of P. berghei LS
MBA, is an inhibitor of ADP ribosyltransferase and is
known to induce differentiation in mouse ESCs within
3 days of exposure (Smith, 1991). To assess the suitability
of MBA-differentiated mouse ESCs as a model to study LS
of P. berghei, we exposed two mouse ESC lines, JM8.N4
and E14, originally derived from C57Bl6/N (Pettitt et al.,
2009) and 129P2/OlaHsd mice (Hooper et al., 1987),
respectively, to MBA. Treatment of both cell lines with
MBA for 72 h resulted in a monolayer of large, flat, terminally differentiated cells (Figures 1A and S1A). In our experience, JM8.N4 mouse ESCs show more uniform differentiation compared to E14 mouse ESCs, which still have a few
colonies of undifferentiated cells left after MBA treatment.
Upon infection with freshly isolated GFP-expressing
P. berghei sporozoites, a range of parasite sizes were observed
in both MBA-differentiated and -undifferentiated JM8.N4
and E14 cells (Figures 1B and S1B). On average, MBA-differentiated JM8.N4 cells showed significantly larger EEFs at
48 h post-infection (hpi) and 64 hpi compared with EEFs
in undifferentiated JM8.N4 mouse ESCs (Figure 1B). Similarly, MBA-differentiated E14 cells showed large EEFs at
48 hpi. However, due to the presence of several small
EEFs in remaining undifferentiated colonies of cells, the
average EEF size was not significantly larger than EEFs in
control E14 undifferentiated cells (Figure S1B). Completion
of LS development was marked by release of infectious merosomes from both MBA-differentiated JM8.N4 and E14
cells between 60 and 72 hpi (Figures 1C and S1C). Only
the supernatant of MBA-differentiated mouse ESCs yielded
blood stage infection when injected into mice (Figures 1D
and S1D). Furthermore, immunostaining of EEFs in differentiated JM8.N4 and E14 cells with MSP-1 antibody
showed MSP-1 expression around newly formed daughter
nuclei in a distinct invaginating pattern (Figures 1E and
S1E), thus indicating maturation of liver schizonts. Overall,
our results demonstrate that treatment with MBA is a
robust differentiation protocol which renders JM8.N4
and E14 mouse ESCs fully supportive of P. berghei LS
development.
RNA Sequencing Reveals Transcriptional Profile of
MBA-Differentiated Mouse ESCs
We determined the transcriptional changes induced
within host cells after MBA treatment, through RNA
sequencing (RNA-seq). A principal component analysis revealed no major batch effects between biological triplicates performed for each treatment, i.e., differentiated
versus undifferentiated cells (Figure 2A). Differential
gene expression analysis performed using Bioconductor

Figure 1. MBA-Differentiated JM8.N4
Mouse ESCs Support Complete P. berghei
LS Development
(A) Morphology (bright-field image) of MBAand DMSO (control)-treated JM8.N4 mouse
ESCs on day 3 of differentiation.
(B) A fluorescence image panel of host cell
nuclei and EEFs stained with DAPI (blue) and
anti-GFP Alexa Fluor 488 antibody (green),
respectively. A graph of EEFs sizes in DMSO(gray) and MBA-treated (red) JM8.N4 mouse
ESCs quantified through HTS Cellomics automated microscopy. Student’s t test was performed on mean parasite size from three independent experiments. Asterisk (*)
represents p value < 0.05.
(C) Bright-field and fluorescence image of
merosomes released from infected MBAtreated JM8.N4 mouse ESCs beyond 60 hpi.
(D) Five Theiler’s original (TO) mice were
injected per condition with cell culture supernatant from infected, MBA- and DMSOtreated (undifferentiated) JM8.N4 cells at
72 hpi.
(E) MSP-1 expression in 65 hpi EEFs in MBAdifferentiated JM8.N4 cells visualized by
staining with mouse anti-MSP1 primary
antibody and anti-mouse Alexa Fluor 555
secondary antibody (red) to visualize. DAPI
(blue) and anti-GFP Alexa Fluor 488 antibody
(green) staining shows nuclei and EEFs,
respectively.
Scale bars, 250 mm (A) and 50 mm (B, C, and
E).

package, DESeq, revealed 11,110 and 13,551 genes differentially expressed (DE) in MBA-differentiated JM8.N4 and
E14 cells, respectively, with 9,366 DE genes common
between the two cell lines. In particular, MBA-induced differentiation resulted in upregulation of smooth musclerelated genes, downregulation of pluripotency genes,
and upregulation of host malaria LS-related genes in
both JM8.N4 and E14 cells (Figure 2B). MBA differentiation coincided with a substantial downregulation of pluripotency markers, such as Nanog, Rex2, and Oct3/4. Loss
of Oct3/4 expression was confirmed through flow cytometry and microscopy in MBA-differentiated cells immunostained with anti-mouse Oct3/4 antibody (Figure S2).
Furthermore, both MBA-differentiated JM8.N4 and E14
cells showed upregulation of several smooth muscle
markers, such as smooth muscle actin 2 (Acta2), transgelin
(Tagln), caldesmon (Cald1), and calponin 1 (Cnn1). A previous study has also reported increased expression of
these genes in mouse ESC-derived contractile smooth
muscle cells (Potta et al., 2009). Other genes, such as col-

ony-stimulating factor 1 (Csf-1), filamin C gamma (Flnc),
parvin alpha (Parva), cluster of differentiation 44 (Cd44),
myosin 1C (Myo1C), claudin 6 (Cldn6), platelet/endothelial cell adhesion molecule 1 (Pecam1), smoothelin
(Smtn), vinculin (Vcl), and calsyntenin 3 (Clstn3), known
to be expressed in vascular smooth muscle cells (Sobue
et al., 1999), were also found to be upregulated postMBA differentiation. On comparison of transcriptome of
MBA-differentiated mouse ESCs to transcriptomes of
other cell types available on the MGI-Mouse Gene Expression Database (including smooth muscle cells) very low
Pearson correlation values with maximum correlation
(Pearson’s r = 0.1) to trophoblast stem cell line R1AB
(Table S1) was observed. Interestingly, a previous study
has reported that trophoblast progenitor cells derived
from the chorion express smooth muscle actin, vimentin,
and b3 tubulin (Genbacev et al., 2011). In the context of
LS infection, expression of typical hepatocyte markers
such as albumin, tryptophan 2,3-dioxygenase, and liver
fatty acid binding protein (Lfabp) was not identified in
Stem Cell Reports j Vol. 14 j 1123–1134 j June 9, 2020 1125

Figure 2. MBA-Differentiated Mouse ESCs Lose Expression of Pluripotency Markers and Upregulate Smooth Muscle Cell Markers
(A) A principal component analysis plot showing the first (PC1) and second principal component (PC2) separating the three biological
replicates of undifferentiated and MBA-differentiated, JM8.N4 and E14 mouse ESCs, into separate clusters.
(B) A heatmap showing differentially expressed smooth muscle markers (red), pluripotency markers (blue), and genes previously implicated in malaria LS infection (green). Upregulation and downregulation are shown in red and blue, respectively.
MBA-differentiated JM8.N4 and E14 cells, confirming the
lack of characteristic hepatocyte-like features. However,
host factors previously implicated in malaria LS infection,
such as cluster of differentiation 81 (Cd81), protein kinase
C zeta (Prkcz), and hepatocyte growth factor receptor
(Hgfr) (Carrolo et al., 2003; Prudêncio et al., 2011; Silvie
et al., 2006) were upregulated in both JM8.N4 and E14
cells after MBA differentiation. Scavenger receptor class
B type 1 (Scarb1), another host gene implicated in malaria
LS infection (Yalaoui et al., 2008), was found to be upregulated only in MBA-differentiated E14 cells.
A gene ontology term enrichment analysis of genes DE in
MBA-differentiated mouse ESCs (Table S2) revealed enrichment of lipid and amino acid metabolic processes, generation of precursor metabolites and energy, cytoskeleton organization, metal ion transport, Golgi vesicle transport,
and pyrimidine ribonucleotide metabolic process among
others. This indicates a highly metabolically active
state of MBA-differentiated cells compared with their
undifferentiated counterparts. Overall, our RNA-seq findings explain the conduciveness of MBA-differentiated
mouse ESCs for development and maturation of P. berghei
EEFs despite lacking typical hepatocyte features but probably sufficing the nutritional requirements of rapidly
growing EEFs.
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ATGL Is Dispensable for Development of P. berghei
EEFs
Pnpla2, or patatin-like phospholipase domain-containing
protein 2, codes for a 486-amino-acid-long protein called
ATGL. ATGL hydrolyses triacylglycerols (TAGs) into diacylglycerol (DAG) and free fatty acid molecules in lipid storage
organelles, such as lipid droplets (LDs). Previous studies
have shown that the lipidome of P. berghei infected Huh7
human hepatoma cells changes significantly with a major
alteration in neutral lipids, such as TAG, DAG, and cholesterol esters, suggesting that host lipogenesis and lipolysis
pathway are engaged during P. berghei LS infection (Itoe
et al., 2014). Interestingly, we found a decrease in the
mean fluorescence intensity (MFI) of EEFs (measured by
flow cytometry) in Huh7 cells transfected with PNPLA2specific siRNA as compared with control transfected cells
(Figure 3A). This suggests a negative impact on the development of intrahepatic parasites when host TAG hydrolysis
and fatty acid mobilization is impaired in Huh7 hepatoma
cells. On the contrary, Pnpla2-deficient mice show accumulation of LDs in hepatocytes, however, they are fully susceptible to P. berghei LS infection (Itoe et al., 2014). This
discrepancy in results between PNPLA2 gene knockdown
in vitro and gene knockout in mice (in vivo) could be due
to off-target effects of PNPLA2 siRNA or the inaccuracy of

Figure 3. ATGL Is Dispensable for P. berghei EEF Development
(A) Huh7 human hepatoma cells were reverse transfected with control siRNA, PNPLA2 siRNA, or transfection reagent (no siRNA). Twentyfour hours later 50,000 freshly isolated, GFP-expressing P. berghei sporozoites were added to each well and MFI was quantified at 48 hpi.
Error bars represent standard deviation of the mean of two independent biological replicates.
(B) A schematic diagram showing biallelic targeting with CRISPR/Cas9 in mouse ESCs.
(C) Pnpla2 ‘‘critical’’ exon was PCR amplified from genomic DNA of wild-type and Pnpla2/ E14 mouse ESCs and sequenced. Cas9-damaged
Pnpla2 allele showed a 5-bp deletion compared with wild-type Pnpla2 highlighted in black. F and R stand for forward and reverse strands,
respectively.
(D) Pnpla2/ and wild-type E14 cells fixed and stained with oil red O (ORO) and DAPI to visualize LDs and nuclei, respectively (scale bar,
100 mm). Western blot was performed on total cell lysate from Pnpla2/ and wild-type E14 mouse ESCs.
(E) A widefield fluorescence image showing infected MBA-differentiated Pnpla2/ and wild-type E14 mouse ESCs stained with DAPI (blue)
and anti-GFP Alexa 488 antibody (green) to visualize host cell nuclei and EEFs respectively at 48 hpi. Scale bar, 100 mm.
(F) EEF size distribution quantified through HTS Cellomics automated microscopy is shown for a representative experiment (BR1) at 48 hpi.
Student’s t test was performed on mean parasite size from three independent biological replicates (n.s., not significant).
(G) A bar chart showing mean and standard deviation of parasite sizes at 48 hpi in all three biological replicates, BR1, BR2 and BR3.
(H) EEF size at 67 hpi quantified through HTS Cellomics automated microscopy. Mean represents average parasite size across triplicate wells
from one experiment.
liver infection load assay in mice. Thus, we hypothesized
that a more definitive analysis could be provided by Pnpla2
knockout in our MBA-differentiated mouse ESCs model.
Pnpla2 knockout (Pnpla2/) was generated in E14
mouse ESCs using a biallelic targeting strategy (Bressan

et al., 2017) where sequence-specific CRISPR/Cas9 introduces a double-strand break in Pnpla2 and deletion of
the first allele occurs after integration of a drug resistance
cassette from the donor vector through homologous
recombination (Figure 3B). Damage in the second allele
Stem Cell Reports j Vol. 14 j 1123–1134 j June 9, 2020 1127

Figure 4. NLSDM Patient Fibroblasts with
Point Mutations in PNPLA2 Do Not Prevent
P. berghei Infection and Growth
(A) A bright-field image of ORO staining of
lipid droplets (white arrows) in healthy
(control) and patient (diseased) fibroblasts.
Scale bar, 2 mm.
(B) Western blot on total cell lysate from
healthy and patient fibroblasts stained with
rabbit anti-ATGL/PNPLA2 antibody (1:600)
shows absence of PNPLA2 protein (~55 kDa)
in patient fibroblasts. Anti-tubulin staining
was performed as a loading control.
(C and D) (C) Infection rate and (D) MFI for
P. berghei-infected diseased and control fibroblasts quantified by flow cytometry at
48 hpi. Error bars represent mean ± standard
deviation of triplicates. Data shown are from
a representative experiment out of two biological replicates.
(E) A representative confocal microscopy
image showing P. berghei EEFs stained with
anti-GFP Alexa Fluor 488 antibody in diseased
and control fibroblasts at 48 hpi. Host cell
nuclei were stained with DAPI. Scale bar,
20 mm.
is repaired through non-homologous end-joining which
is an error-prone DNA repair mechanism often leading
to frameshift mutations. Pnpla2 gene disruption was
confirmed in Pnpla2/ E14 mouse ESCs through genotyping, which showed a 5-bp frameshift deletion in the
‘‘critical’’ exon (Figure 3C). Furthermore, MBA-differentiated Pnpla2/ E14 cells showed substantial accumulation
of large LDs in their cytosol as shown by oil red O staining
of neutral triglycerides, and lacked ATGL protein
compared with wild-type cells (Figure 3D). The enlargement and accumulation of LDs in mutant cells is thought
to occur due to accumulation of TAGs in LDs after
impaired interaction of ATGL with the LDs (Kobayashi
et al., 2008).
After confirmation of Pnpla2 disruption and loss of ATGL
protein, MBA-differentiated Pnpla2/ and wild-type E14
cells were infected with P. berghei sporozoites. At 48 hpi,
the average parasite size in Pnpla2/ E14 cells was slightly
lower than in wild-type cells; however, this was not statistically significant (Figures 3E–3G). The total number of
EEFs was also similar in both wild-type and mutated Pnpla2
host genetic backgrounds (Figure S3). This suggests that
sporozoite to EEF conversion is not affected in the absence
of ATGL protein. To further check if the slight difference in
EEF sizes observed at 48 hpi increased at later time points,
parasite size was measured at 67 hpi and found to be similar
in Pnpla2/ and wild-type E14 cells (Figure 3H). These
findings clearly indicate that Pnpla2 is dispensable and is
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not required for P. berghei LS development in MBA-differentiated cells.
NLSDM Patient Fibroblasts Are Permissive to P. berghei
Infection and Growth
Mutations in human PNPLA2 gene causes neutral lipid
storage disease with myopathy (NLSDM) characterized by
severe accumulation of TAGs in cytoplasmic LDs in neutrophils, liver, muscle, and heart (Kobayashi et al., 2008;
Schweiger et al., 2006). To test if natural genetic variation
in PNPLA2 affects susceptibility to malaria LS infection,
we obtained two NLSDM patient dermal fibroblast lines
F121-12N-YC280270 and F122-12N-LB141159 carrying
mutation in exon 5 (613dupC) and exon 8 (1051delC),
respectively (Reilich et al., 2011). Two healthy dermal fibroblast lines, F011-11N-RM01/02 and F097-12N-BH-01/02,
were also received from the same source to be used as
healthy controls in sporozoite infection assays. NLSDM patient fibroblasts showed accumulation of LDs in the cytosol
and lacked ATGL protein when compared with healthy fibroblasts (Figures 4A and 4B). To check if LS phenotype
observed in Pnpla2/ E14 mouse ESCs could be reproduced in NLSDM fibroblasts, patient and healthy fibroblasts were infected with GFP-expressing P. berghei sporozoites in parallel. Both healthy and patient fibroblasts showed
comparable infection rates at 48 hpi (Figure 4C). Furthermore, patient fibroblast line labeled ‘‘Diseased 1’’ showed
slightly higher MFI than the two healthy control fibroblast

lines. However, the MFI of second patient fibroblast line
labeled ‘‘Diseased 2’’ was comparable with healthy fibroblasts (Figure 4D). These results were validated through
confocal microscopy where EEFs in patient and healthy fibroblasts looked comparable in size at 48 hpi (Figure 4E).
It is clearly evident from these results that both patient
and healthy fibroblast lines show variation in infection
rate and/or MFI value between themselves. This could be
due to difference in their genetic background. To avoid being confounded by difference in host genetic backgrounds
contributing to variation in infection and parasite development between fibroblast lines, PNPLA2 knockdown was
performed in healthy fibroblast line F011-11N-RM-01/02
(Control 1) and infected with P. berghei sporozoites to determine the role of PNPLA2 during LS infection (Figure S4).
PNPLA2 transcript knockdown measured by qRT-PCR
showed only 16% of transcript remaining in healthy fibroblasts at 48 h post-transfection (i.e., 84% transcript knockdown) compared with control siRNA transfected fibroblasts
(Figure S4A). P. berghei infection rate and MFI in PNPLA2
siRNA transfected fibroblasts was not significantly different
from control transfected cells (Figures S4B and S4C). This
confirms that the reduced EEF development observed in
PNPLA2 knockdown Huh7 hepatoma cells (Figure 3A)
could not be reproduced, both, in MBA-differentiated
Pnpla2/ E14 mouse ESCs, and, NLSDM patient fibroblasts. Thus, PNPLA2 protein is dispensable for P. berghei
LS infection in both, differentiated mouse ESCs, and, human fibroblasts. Overall, these results highlight the utility
of MBA-differentiated mouse ESCs to validate the role of
candidate host genes previously identified through gene
knockdown approaches which may have frequent offtarget hits leading to false positives.
iHLCs Do Not Support Complete Development and
Maturation of P. berghei EEFs
The use of NLSDM fibroblasts above illustrates the potential of exploiting genetic variation in primary cells from
different human donors to understand host-pathogen interactions. Dozens of candidate loci in the human genome
have been linked to severe malaria in humans through
genome wide association studies (Malaria Genomic Epidemiology Network et al., 2015; Timmann et al., 2012). Libraries of human iPSCs are now becoming available that
reflect much of the most abundant variation in the human
genome (Agu et al., 2015; Soares et al., 2014). We, therefore,
tested if human ESC- or iPSC-derived hepatocyte-like cells
can be used as a model to study Plasmodium LS infection.
In this study, we utilized iHLCs derived through a 25- to
35-day-long differentiation of human ESCs or iPSCs into
definitive endoderm cells, which gave rise to hepatic progenitors eventually maturing into hepatocytes (Hannan
et al., 2013). iHLCs generated by this protocol have been

characterized previously and display hepatic characteristics, such as expression of albumin, alpha fetal protein,
glycogen storage, and cytochrome activity from day 20 onward. Basic hepatic metabolic functions start to appear
from day 25 onward with increasing maturation up to
day 35 (Touboul et al., 2010). The number of days required
for hepatoblast maturation into iHLCs may vary between
different cell lines and needs to be optimized in each case
(Hannan et al., 2013).
In this study, we derived wild-type A1ATcorr iHLCs from
A1ATcorr hiPSCs (Yusa et al., 2011) and observed for any
morphological and phenotypic traits similar to primary hepatocytes. A1ATcorr iHLCs show a typical hepatocyte-like
polygonal morphology with binucleate cells (Figure 5A)
and express hepatocyte nuclear factor 4a (HNF4a) (Figure 5B), which is a transcription factor required for maintaining hepatic gene expression, bile acids secretion and
lipid (e.g., triglycerides and cholesterol) homeostasis in hepatocytes (Hayhurst et al., 2001). HNF4a has been shown
expressed in nascent hepatic cells, hepatoblasts and differentiated hepatocytes, thus marking liver-specific differentiation (Si-tayeb et al., 2010). Heterogeneous expression of
HNF4a in the nuclei of A1ATcorr iHLCs reflects varied
extent of differentiation of each cell. This is corroborated
by previous studies which have shown that only 60% of
iHLCs show HNF4 a expression and 80% show albumin
expression which is another marker of hepatocyte differentiation (Si-tayeb et al., 2010; Touboul et al., 2010). No
HNF4a expression was detected in undifferentiated A1ATcorr hiPSCs nuclei (negative control) (Figure 5B). Having
confirmed the hepatocyte-like features of iHLCs, we systematically studied P. berghei infection, growth and maturation in them. As shown in Figure 5C, the infection rate (percentage of infected host cells) in A1ATcorr iHLCs infected
with P. berghei sporozoites was about 0.21%, which was
significantly lower compared with 0.53% in Huh7 human
hepatoma cells (used as a comparator) at 48 hpi. Further
development of P. berghei EEFs at 48 hpi was assessed by
measuring parasite size using automated imaging.
Although multiple parasite daughter nuclei were observed
in both cell types, the average parasite size in A1ATcorr
iHLCs was about 136.13 mm2 compared with slightly
higher 156.30 mm2 in Huh7 cells (Figure 5D). A frequency
distribution of EEF size in A1ATcorr iHLCs was similar to
Huh7 cells except that fewer large EEFs between 300 and
600 mm2 were present in iHLCs at 48 hpi (Figure 5E).
Finally, the maturation of EEFs in A1ATcorr iHLCs was studied by staining infected cells with anti-MSP-1 antibody.
MSP-1 is expressed in the plasma membrane of late liver
schizonts and marks late LS maturation (Sturm et al.,
2009). The pattern of MSP-1 staining in parasite plasma
membrane indicates the extent of EEF maturation and
membrane invagination around newly formed daughter
Stem Cell Reports j Vol. 14 j 1123–1134 j June 9, 2020 1129

Figure 5. iHLCs Do Not Support Complete
Development of P. berghei EEFs
(A) A bright-field image of iHLCs showing
polygonal, binucleate (white arrows) hepatocyte-like morphology.
(B) HNF4a expression in iHLCs and undifferentiated hiPSCs visualized by staining
with goat anti-HNF4a primary antibody and
anti-goat Alexa Fluor 596 secondary antibody (purple). Host cells were stained with
DAPI (blue). Images are representative of
more than three independent differentiations.
(C) Infection rate in A1ATcorr iHLCs and
Huh7 cells at 48 hpi quantified by flow
cytometry. Data represent mean ± standard error of the mean of three independent experiments. Student’s t test
was performed on mean of technical
replicates from three independent experiments. p value < 0.05 shown as
asterisk (*).
(D) EEF size in A1ATcorr iHLCs and Huh7
cells at 48 hpi. Mann-Whitney test was
applied to test for statistically significant difference. Data represented from
triplicate wells of a representative
experiment. n.s., not.
(E) A frequency distribution (as percentage) of EEF sizes in A1ATcorr iHLCs
and Huh7 cells at 48 hpi.
(F) A representative confocal image of
GFP-expressing EEFs in A1ATcorr iHLCs
and Huh7 cells stained with anti-MSP-1
antibody (red) and DAPI (blue) at
65 hpi.
(G) Merosome-like structures released at 72 hpi from infected A1ATcorr iHLCs and Huh7 cells were injected intravenously
into TO mice from two independent experiments. Combined data are shown from both experiments.
Scale bars, 100 mm (A and B) and 20 mm (F).
nuclei (Graewe et al., 2011). EEFs in A1ATcorr iHLCs
showed abnormal pattern of MSP-1 staining at 65 hpi, lacking segregation of newly formed daughter nuclei into
distinct units (Figure 5F). This is characteristic of delay in
maturation of EEFs. In contrast, Huh7 EEFs showed a
typical grape-like pattern of MSP-1 staining around individual daughter parasites (Figure 5F). Keeping infected cultures beyond 65 hpi (up to 96 hpi) resulted in occasional
release of few merosome-like structures from A1ATcorr
iHLCs but these did not produce blood stage infection in
Theiler’s original (TO) mice upon intravenous injection.
On the contrary, merosomes released from infected Huh7
cells (control) always produced a positive blood stage infection in mice (Figure 5G). Overall, these results suggest that
A1ATcorr iHLCs are susceptible to P. berghei infection but
EEFs do not attain complete maturation in them. To rule
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out inappropriate host genetic background as a possible
cause of stunted parasite growth, iHLCs derived from H9
human ESCs (Thomson et al., 1998) and BBHX8 human
iPSCs (Rashid et al., 2010) were infected with P. berghei sporozoites. None of the two genetic backgrounds supported
complete maturation of P. berghei EEFs as well (Figure S5).
In conclusion, our results show that iHLCs are a suboptimal model to study LS of P. berghei parasites.

DISCUSSION
We have shown that differentiation with MBA dramatically
increases permissiveness of JM8.N4 and E14 mouse ESCs to
P. berghei sporozoite infection in contrast to undifferentiated cells. Transcriptional profiling post-MBA differentiation revealed increase in expression of several smooth

muscle-related genes but lack of typical hepatocyte
markers. Nonetheless, complete development of P. berghei
EEFs in this model may be attributable to the expression
of Scarb1, Met, Cd81, Hgfr, and Prkcz; host genes previously
implicated in malaria LS infection. In addition, significant
enrichment of lipid, amino acids, and ribonucleotide metabolic processes along with vesical transport pathways may
indicate nutritionally rich and metabolically active host
cell environment post-MBA differentiation. We have
clearly demonstrated the utility of this infection model to
validate LS phenotypes previously associated with candidate host genes identified in gene knockdown studies. In
particular, we established that host Pnpla2 involved in
neutral lipid mobilization is dispensable for P. berghei LS
infection in MBA-differentiated mouse ESCs. We corroborate this finding by showing that there is no significant difference in P. berghei LS infection between NLSDM patient
fibroblasts and healthy fibroblasts.
Plasmodium parasites can synthesize fatty acids using the
type II fatty acid synthesis (FAS II) pathway. This may
possibly explain why lack of Pnpla2 which hydrolyses
TAGs to release fatty acids and DAGs does not impact
growth of P. berghei EEFs. Another possibility could be
involvement of redundant genes/pathways which may
become a substitute for ATGL in Pnpla2 knockout cells.
Discrepancy in infection phenotype between PNPLA2
siRNA knockdown and Pnpla2 gene knockout could be
due to off-target effects of siRNAs leading to false positive
hits thus requiring validation in a gene knockout system.
The widely used CRISPR/Cas9 system can introduce precise
mutations in any genomic loci with minimal off-target effects to mutate or correct gene/s of interest in diverse
mammalian cell lines, including stem cells (Ding et al.,
2013; Gaj et al., 2013). This outlines a major advantage of
developing stem cell-based malaria LS infection model.
Overall, our results are a proof-of-principle that MBA-differentiated mouse ESCs can be used for future gene-infection
phenotype validation studies along with identification of
new host-parasite interactions occurring during malaria
LS infection.
Next, we tested if a hESC- or hiPSC-based malaria LS
infection model can be developed as this would allow us
to recapitulate human genetic variation occurring in primary cells of donors and study its effect on malaria LS infection. We showed that iHLCs derived from hiPSCs (A1ATcorr and BBHX8) or hESCs (H9) can be infected with
P. berghei sporozoites, but do not support functional maturation of EEFs into segmented liver schizonts and infectious merosomes. This could be due to lack of one or
more host factors in iHLCs known to affect growth and
maturation of Plasmodium LS. Some of the host factors
known to affect invasion and EEF development include,
L-FABP which is possibly involved in delivering fatty acids

to parasitophorous vacuole via interaction with PVM protein UIS3 (Labaied et al., 2007), SRB1 which plays a role
in Plasmodium sporozoite entry and possibly supplies
cholesterol required for EEF growth (Yalaoui et al., 2008),
and host kinases PKCzeta whose knockdown leads to
reduced parasite load in vitro and in vivo (Prudêncio et al.,
2008). In addition, host metabolism, immunity, apoptosis
and ER stress-related pathways have also been previously
implicated in parasite growth and survival (Albuquerque
et al., 2009). Furthermore, incomplete EEF development
in iHLCs could be due to acquisition of anti-parasitic factors or immune-competency during maturation into hepatocyte-like cells. Previous studies have shown that cellautonomous host defense mechanisms, such as interferon
induced reactive oxygen and nitrogen species, immunityrelated GTPases mediated disruption of parasitophorous
vacuole, autophagy, and nutrient restriction, are major
strategies used by a diverse range of primary cells to target
intracellular protozoa such as Leishmania, Toxoplasma, Plasmodium, and M. tuberculosis (MacMicking, 2012, 2014). In
context with P. berghei LS infection, Liehl et al. (2014)
showed that Plasmodium RNA is recognized by pattern
recognition receptor in infected hepatocytes which induces a type I interferon response responsible for recruiting
liver leukocytes to eliminate intracellular EEFs. In contrast,
undifferentiated mouse ESCs are known to lack strong
immunological response when infected with bacterial
pathogens such as Salmonella and Shigella in vitro (Yu
et al., 2009). This could possibly mean that as ESCs differentiate into primary hepatocytes they gain host defense
factors required for targeting intracellular pathogens. In
fact, Ng et al. show that hepatoblasts are more permissive
to P. falciparum infection than developmentally mature
iHLCs.
While our study shows that iHLCs are a sub-optimal
model to study LS infection, a previous study demonstrated
that P. falciparum, P. vivax, P. yoelii, and P. berghei EEFs can
mature in stem cell-derived hepatocytes (Ng et al., 2015).
The discrepancy between our results could be due to use
of different human PSC lines in the two studies, which
may present variably suitable host genetic background to
support infection and/or to form fully mature hepatocyte-like cells. Ng et al. reported formation of large, multinuclear, MSP-1 expressing liver schizonts in iHLCs, however, release of infectious merosomes from the host cell has
not been addressed. In our opinion, one of the major challenges which remains to be tackled to develop successful
stem cell-based LS models is to further improve hepatocyte
differentiation protocols to generate fully mature, adult
primary hepatocyte-like cells from diverse human stem
cell lines instead of featuring fetal hepatocyte characteristics (Baxter et al., 2015). Molecules such as cyclic AMP
and other small molecules have been shown to increase
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maturation of iHLCs (Ogawa et al., 2013; Shan et al., 2013)
and may facilitate development of better iHLC-based
models in future. In addition, it is possible that essential
nutrients such as D-glucose may have limited availability
to EEFs in iHLCs. Previous research has shown that a minimum of 2,000 mg/L/day of D-glucose is essential for LS
maturation (Itani et al., 2014). Thus, in future, efforts can
be focused on optimizing iHLC media composition and
culture conditions to promote complete LS maturation.
Overall, this study assessed the suitability of both, mouse
and human PSC-based P. berghei LS infection models. iHLCs
prove to be a sub-optimal infection model, however, MBAdifferentiated mouse ESCs should enable the validation
and discovery of new host-parasite interactions which are
essential for P. berghei intrahepatic development and can
be targeted to devise novel therapeutic interventions to
treat malaria.

EXPERIMENTAL PROCEDURES
Resource Availability
The accession number for the RNA sequencing data reported in
this paper is European Nucleotide Archive: ERP121187.

Cell Lines, Parasite Lines, and Sporozoite Infection
Assay
JM8.N4, E14, Huh7, and fibroblasts were maintained in their
respective media at 37 C in 5% CO2. Human iPSCs and ESCs
were maintained in a chemically defined medium and differentiated into iHLCs using a previously published protocol (Hannan
et al., 2013). PbGFPcon parasite line was used for all sporozoite infections. Full details on media composition and infection assay are
provided in Supplemental Experimental Procedures.

MBA Differentiation of Mouse ESCs
E14 and JM8.N4 mouse ESCs were differentiated using 9 mM and
7 mM MBA treatment, respectively, for 3 days. Full details are provided in Supplemental Experimental Procedures.
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Gonçalves, L.A., Carret, C., Dorkin, R., Röhl, I., Jahn-Hoffmann,
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A bright field image showing morphology of MBA-treated E14 mouse ESCs on day 3 of differentiation.

34

b) A widefield fluorescence image showing infected undifferentiated and MBA differentiated E14

35

mouse ESCs stained with DAPI (blue) and anti-GFP-Alexa-488 antibody (green) to visualize host cell

36

nuclei and EEFs respectively at 48 hpi. Scale bar = 100 μm. Size of EEFs fixed at 48 hpi was

37

quantified in undifferentiated (red) and MBA differentiated (blue) E14 mouse ESCs through automated

38

microscopy. Student’s t- test was performed on mean parasite size from three independent

39

experiments. Key: n. s. = not significant. c) A bright field image of merosomes released from infected

40

MBA differentiated E14 mouse ESCs. Scale bar = 50 μm. d) Two and three TO mice were injected

41

per condition with cell culture supernatant from infected wells from two independent experiments

42

respectively. e) Infected MBA differentiated E14 mouse ESCs were fixed, permeabilized and stained

43

with mouse anti-MSP-1 primary antibody followed by anti-mouse-Alexa Fluor-555 secondary antibody

44

(red) to visualize MSP-1 expression at 65 hpi. DAPI (blue) and anti-GFP-Alexa Fluor-488 antibody

45

(green) staining was performed on the same culture to visualize nuclei and EEFs respectively. Scale

46

bar = 100 μm.

47

48
49

Fig S2: Loss of pluripotent marker expression after MBA treatment. Undifferentiated and MBA-

50

differentiated E14 mouse ESCs were fixed, permeabilized and stained with a) DAPI and mouse anti-

51

Oct3/4 primary antibody followed by donkey anti-mouse-Alexa 488 secondary antibody to visualise

52

host cell nuclei and Oct3/4 transcription factors respectively. The imaging was done using wide field

53

fluorescence microscopy. Scale bar = 100 µm. b) Mouse IgG1 isotype control (red) or mouse Oct3/4

54

specific antibody (blue) (BD Stemflow Human and Mouse Pluripotent Stem Cell Analysis Kit) to

55

quantify undifferentiated (Oct3/4 positive) population by flow cytometry.

56
57
58

59
60

Fig S3: Number of EEFs in WT and Pnpla2 KO E14 cells. Number of EEFs in triplicate wells for

61

three independent experiments. Error bar represents mean ± standard error of means (SEM). Key: n.s

62

= not significant.

63
64

Fig S4: PNPLA2 knockdown in healthy dermal fibroblast does not affect P. berghei infection

65

and growth. a) PNPLA2 transcript level was measured in control and PNPLA2 siRNA transfected

66

healthy fibroblasts by qRTPCR 48 hours after reverse transfection. Error bars represent mean ±

67

standard deviation of duplicates from a representative experiment out of two independent biological

68

replicates. b) Infection rate, and, c) MFI were measured in infected, control, PNPLA2 and no siRNA

69

transfected healthy fibroblasts at 48 hours post infection (hpi) by flow cytometry. Error bars represent

70

mean ± standard deviation of triplicates from a representative experiment. Student’s t test was

71

performed on mean infection rate (b) and MFI (c) from three independent experiments. n.s.= not

72

significant.

73

74

Fig S5: P. berghei LS infection in BBHX8 and H9 iHLCs. a) Infected BBHX8 iHLCs, H9 iHLCs and

75

Huh7 cells were fixed and stained with DAPI to visualize the nuclei (blue) and an anti-GFP-Alexa

76

Fluor-488 antibody (green) to visualize the EEFs at 63 hpi. The EEFs were imaged automatically

77

using the Spot Detector Algorithm. The objects detected by the algorithm are either accepted

78

(denoted by blue ring) or rejected (denoted by orange ring) based on pre-set object selection

79

parameters. b), c) and d) show parasite sizes in BBHX8 and H9 iHLCs at mid and late LS time points.

80

Data shown here is from a representative experiment out of two independent biological replicates. e),

81

f) and g) show sporozoite to EEF conversion (%) for BBHX8 and H9 iHLCs compared to their

82

respective Huh7 controls. Data represents mean ± standard deviation of triplicates from a

83

representative experiment out of two independent biological replicates. h) Infected BBHX8 iHLCs and

84

Huh7 cells were fixed, permeabilized and stained with DAPI (blue) to visualize the nuclei and anti-

85

GFP-Alexa Fluor-488 antibody (green) to visualize the EEFs. MSP-1 was stained with a mouse anti-

86

MSP-1 primary antibody followed by an anti-mouse-Alexa Fluor555 secondary antibody (red). Scale

87

bar = 20 µm. i) Merosome like structures from two independent experiments were injected IV into TO

88

mice.

89
90

Supplementary Experimental Procedures:

91
92

Cell lines, parasite lines and mosquitoes

93

JM8.N4 and E14 mouse ESCs were maintained in Knockout™ Dulbecco's Modified

94

Eagle Medium (DMEM, Gibco) and Glasgow’s Minimum Essential Medium (GMEM,

95

Sigma) respectively supplemented with fetal bovine serum (FBS), L-glutamine, β-

96

mercaptoethanol (BME), non-essential amino acids (NEAA) and 1:10000 (1X)

97

leukemia inhibitory factor (LIF, Millipore ESGRO 1107). Huh7 human hepatoma

98

cells, NLSDM patient and healthy fibroblasts (received from Mojgan Reza,

99

Newcastle Biobank, UK, after approval from the local ethics committee at Sanger

100

Institute) were maintained in DMEM supplemented with FBS. iHLCs maintenance

101

and differentiation method is described below. For all P. berghei sporozoite infection,

102

the PbGFPcon parasite line previously derived from reference clone 15cy1 of the

103

ANKA strain of P. berghei parasites was used (Franke-Fayard et al., 2004).

104

Sporozoites were produced by feeding female Anopheles stephensi mosquitoes on

105

Theiler’s Origin (TO) mice infected with PbGFPcon parasite blood stocks

106

intraperitoneally. All animal work was carried out under licenses from UK Home

107

Office and protocols approved by the ethics committee at the Wellcome Trust

108

Sanger Institute.

109

Sporozoite infection assay

110

P. berghei sporozoites isolated from A. stephensi salivary glands were added on top

111

of cells in a ratio of 1:2 (parasites: cells) followed by centrifugation at 400 rcf, 4 ºC for

112

5 minutes. Infected cultures had a daily change of medium supplemented with 1%

113

Pen/Strep (Gibco) and incubated at 37 ºC in 5 % CO2.

114

MBA differentiation of mouse ESCs

115

A day before MBA treatment, E14 and JM8.N4 mouse ESCs were seeded on gelatin

116

coated 24-well plates and cultured in their respective medium supplemented with

117

0.1X LIF (Millipore, ESGRO 1107). Next day, media containing 9 mM and 7 mM

118

MBA (dissolved in DMSO) was added to E14 and JM8.N4 mouse ESCs respectively.

119

MBA exposure lasted for 72 hours with fresh medium changes every day. After

120

differentiation, MBA was removed and cells were cultured in their respective medium

121

containing 0.1x LIF.

122

Nuclease assisted gene targeting in E14 mouse ESCs

123

Before nucleofection, E14 mouse ESCs were trypsinised and 2 x 10 6 cells were

124

aspirated and centrifuged followed by removal of the supernatant. Next, 100 µl of

125

Amaxa® Human Nucleofector® Kit 2 complete ‘Solution 2’ was added to the cells

126

followed by transfer to the vial containing the prepared DNA (4 μg Cas9 expression

127

plasmid, 2 μg targeting vector plasmid with 1 kb homology arms, 4μg guide RNA

128

expression plasmid) and mixed 2-3 times. The cells-DNA mixture was quickly and

129

gently transferred to the AMAXA nucleofection cuvette and electroporated

130

immediately using the program‘A-23’. Electroporated cells were plated on a gelatin

131

coated Petri dish at various densities to ensure well-separated colonies for picking.

132

Drug selection was applied 3 days post-nucleofection to allow time for

133

transcription/translation of the Cas9 protein and guide RNAs and for homologous

134

recombination to occur. To identify whether the targeted region is successfully

135

disrupted, Long Range PCR (LRPCR) was performed using the LongAmp Taq

136

Polymerase (New England BioLabs Cat# M0323). PCR products amplified from the

137

non-targeted allele were Sanger sequenced.

138
139

Bulk mRNA sequencing

140

The Qiagen AllPrep DNA/RNA/miRNA Universal kit was used for isolating RNA from

141

undifferentiated and MBA-differentiated E14 and JM8.N4 mESCs. A random-primed

142

cDNA library was synthesized using Illumina’s TruSeq Stranded mRNA Sample Prep

143

Kit according. Next, cDNA libraries were amplified with KAPA HiFi Polymerase,

144

quantified and pooled before sequencing on a HiSeq 2500 sequencer (total number

145

of reads were 176,320,531, insert size ~150 bp, 92% reads mapped to M. musculus

146

genome, read length 75bp PE, average fragment length 165bp, average yield per

147

sample = 2895kb > Q20, Run 14037). R Graphical User Interface (v 3.1.3) was used

148

for data analysis.

149

In vitro hepatocyte differentiation

150

Human iPSCs and ESCs were maintained in a chemically defined medium (CDM)

151

containing polyvinyl alcohol (PVA, Sigma), bovine serum albumin (BSA),

152

concentrated lipids, thioglycerols (Sigma-Aldrich), insulin (Roche), transferrin

153

(Roche) and Pen/Strep. To begin differentiation, CDM-PVA containing basic

154

fibroblast growth factor (bFGF) and Activin was added to iPSCs or ESCs on day 1.

155

On day 2, definitive endoderm (DE) differentiation was induced by replacing medium

156

with CDM-PVA containing Activin-A (100ng/mL), bFGF (100 ng/mL), BMP-4 (10

157

ng/mL), LY294002 (10 μM), and CHIR99021 (3 μM) for 24 hours. On Day 3, cells

158

were fed with the same medium without CHIR99021. On day 4, CDM-PVA was

159

replaced with RPMI-B27 medium (RPMI-1640, B27, NEAA and Pen/Strep)

160

containing Activin-A (100 ng/mL), bFGF (100 ng/mL). Next, differentiation of anterior

161

definitive endoderm was induced by incubating cells with RPMI-B27 medium

162

containing Activin-A (50 ng/mL) from day 5 to 7 with media replacement every day.

163

To induce hepatoblast specification, cells were treated with RPMI-B27 medium

164

containing BMP-4 (20 ng/mL) and FGF10 (10 ng/mL) from day 8 to 12 with media

165

replacement every day. From day 12 onwards, cells were allowed to functionally

166

mature by feeding them with hepatocyte basal medium (Lonza CC-3199) containing

167

OSM (30 ng/mL) and HGF (50 ng/mL). A change of medium was provided every

168

alternate day during this phase of the protocol.

169

Western Blotting

170

Cell pellets were lysed in 1x LDS lysis buffer and boiled at 95°C for 10 minutes. Total

171

protein concentration was measured through UV-protein estimation method and

172

increasing amount of protein (20 µg to 150 µg) was loaded on NuPAGE® Novex® 4-

173

12% Bis-Tris Protein Gel in 1x running buffer and run at 200 V for 50 minutes.

174

PageRuler™ Prestained Protein Ladder (10 to 180 kDa, Life Technologies (#26616))

175

was used for size determination. Proteins were transferred from NuPAGE® protein

176

gel to nitrocellulose membrane (0.45 µ) at 30 V for 2 hours. Thereafter, the

177

nitrocellulose membrane was blocked in 5% milk for 2 hours at room temperature

178

(25°C) followed by overnight incubation with primary antibodies diluted (1:500) in

179

blocking solution at 4°C with gentle shaking. All secondary antibodies were diluted

180

(1:10000) in blocking solution and incubated with nitrocellulose membrane for 1.5

181

hours at room temperature (25°C) with gentle shaking. Proteins were detected on

182

stained nitrocellulose membrane using the Amersham ECL Western Blotting

183

Detection Reagent (GE Healthcare Life Sciences) according to the manufacturer’s

184

instructions.

185

Flow Cytometry

186

Flow cytometry samples were prepared by trypsinizing cells for 3 minutes at 37 ºC

187

and stopping the reaction with appropriate ice-cold cell culture medium containing

188

10% FBS. A single cell suspension was achieved through repeated pipetting and

189

centrifuged at 1100 rpm, 4 ºC for 3 minutes. The supernatant was aspirated and the

190

cell pellet was washed with ice-cold 1% FBS solution in 1x PBS and centrifuged at

191

1100 rpm, 4ºC for 3 minutes. Finally, the pellet was re-suspended in 300 µl of 1%

192

FBS solution and placed on ice. Infected cells were detected on the BD Fortessa by

193

gating events on FSC vs SSC and GFP/Alexa 488 vs Alexa 647 dot plots. FlowJo (v

194

7.6.5) was used for data analysis. Please note, MBA differentiated mouse ESCs

195

could not be recovered as intact single-cell suspension by enzymatic treatment and

196

pipetting, thus, precluding infection quantification by flow cytometry based assay.

197

siRNA Reverse Transfection

198

Before transfection, 20 µM ATGL siRNA stock solution (Dharmacon) was diluted to a

199

2 µM ATGL siRNA working solution in RNase-free water. A pre-dilution of the siRNA

200

was made in OptiMEM® (Gibco, cat#31985) by adding 1.5 µL of siRNA working

201

solution to 8.5 µL of OptiMEM® and mixing gently. Next, a pre-dilution of

202

Lipofectamine® RNAi MAX was made by gently mixing 0.2µL Lipofectamine® in 10

203

µL OptiMEM®. The siRNA pre-dilution and Lipofectamine® pre-dilution solutions

204

were mixed 1:1, mixed gently and incubated for 20 minutes at room temperature.

205

Then, 20 µL of the siRNA/Lipofectamine® complexes was transferred to a new 96

206

well plate for cell culture. About 6000 cells were added per well in 80 µl final volume

207

of RPMI 1640 supplemented with 10% FBS, 1% L-Glutamine, 1% NEAA and 1%

208

HEPES. Edge wells were filled with water or PBS. The cells were incubated for 48h

209

at 37ºC in 5% CO2 incubator.

210
211

Immunofluoroscence assay and microscopy

212

Cells were fixed with 4% PFA followed by permeabilization with 0.1% saponin. For

213

blocking, cells were incubated with 1% BSA and 0.05% saponin solution in PBS for 1

214

hour. All primary antibodies (GFP-Alexa Fluor 488, Life Technologies; MSP-1,

215

courtesy Anthony Holder at Francis Crick Institute, UK; HNF4a, SantaCruz sc6556;

216

ATGL, Cell Signaling Technology #2138) were diluted in blocking solution and

217

incubated with cells for 2 hours, followed by three washes with PBS. All secondary

218

antibodies and the DNA staining dye DAPI (1:3000) were diluted in blocking solution

219

and incubated with cells for 45 minutes in the dark. The High Content Screening

220

(HCS) Thermo Scientific Cellomics imaging platform was used for image acquisition

221

using the ‘Acquire Only’ algorithm. Cells were imaged at 200x magnification in DAPI

222

and Alexa-488 channels with exposure times optimised beforehand. For parasite

223

number and size quantification, ‘Spot Detector’ algorithm in HCS Studio Cellomics

224

Scan software was used with object detection threshold determined before analysis.

225

Late stage parasites stained with anti-MSP 1 antibody in iHLCs were imaged using

226

Zeiss LSM 410 confocal microscope at 400x magnification.

227

Oil Red O staining

228

ORO powder (Sigma) was dissolved in 60 % isopropanol (in water) to prepare a 0.2

229

% solution and filtered through Whatman filter paper. Fixed cells were stained for 30

230

minutes with ORO solution and washed afterwards with 1X PBS.

231
232
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